Literature DB >> 14535199

Effects of "moxibustion serum" on proliferation and phenotypes of tumor infiltrating lymphocytes.

Yunfei Chen1, Cuiying Zhao, Hanping Chen, Huilian Qin, Fang Fang.   

Abstract

Tumor infiltrating lymphocytes (TIL) were cultured with "moxibustion serum" (MS), and the results were examined by flow cytometry. The results indicated that MS could enhance the proliferation of TIL, accelerate it to reach the exponential growth phase, and assist recombinant interleukin 2 (rIL-2) to enhance successively the percentage of CD3+ positive cells, maintain the number of CD4+ positive T cells, promote greatly the percentage of CD8+ positive T cells among TILs, and reverse the CD4+/CD8+ ratio. Such cooperative effects rely on relative specificity of acupoints. It is suggested that MS is beneficial to the growth of TIL both in the aspects of proliferation and phenotypes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14535199

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  4 in total

1.  Enhanced expression of epidermal growth factor receptor gene in gastric mucosal cells by the serum derived from rats treated with electroacupuncture at stomach meridian acupoints.

Authors:  Zong-Bao Yang; Jie Yan; Xiao-Ping Zou; Shou-Xiang Yi; Xiao-Rong Chang; Ya-Ping Lin; Xi-Ping Li
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

2.  Numerical Simulation of Temperature Distribution during Mild Moxibustion.

Authors:  Honghua Liu; Zhiliang Huang; Lei Wei; He Huang; Qian Li; Han Peng; Mailan Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-16       Impact factor: 2.650

3.  Prospective tests on biological models of acupuncture.

Authors:  Charles Shang
Journal:  Evid Based Complement Alternat Med       Date:  2007-11-21       Impact factor: 2.629

Review 4.  The research of acupuncture effective biomolecules: retrospect and prospect.

Authors:  Yu Wang; Lei-Miao Yin; Yu-Dong Xu; Yan-Yan Lui; Jun Ran; Yong-Qing Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-02       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.